Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
| Press Release Montrouge, France, January 3, 2018 |
DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 a.m. PST in San Francisco, CA.
A live webcast of the Company's presentation at the J.P. Morgan Conference will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 24 hours after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Investor Relations Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
[email protected]
DBV Media Contact
Roberta Di Giorgio
Head, Corporate Communications
+1 917-612-2861
[email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/a9d72e3d-d35b-43aa-aadf-91a2e61912d7
